Safety and Efficacy of Acarbose+Saxagliptin Compared With Metformin+Saxagliptin in Patients With Type 2 Diabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.
Also called NCT02605772
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 100 participants
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
- Registry
-
NCT02605772
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT02605772. Randomized; no masking; primary purpose treatment. Start 2015-12 (registry gives no type); primary completion 2016-11 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of Acarbose+Saxagliptin Compared With Metformin+Saxagliptin in Patients With Type 2 Diabetes
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Acarbose
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Saxagliptin
- Lead sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
Record details
- Record id
cardio:ct-nct02605772- Content hash
a86dc0b2868c36e962861216d4f27a4441b0a919e40f1dda8835c74f37bed6bb